Compare · Head-to-head
FOXO4-DRI vs Humanin.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with Humanin, then use the table to confirm fit.
Humanin is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
FOXO4-DRI
Preclinical senolytic peptide that disrupts FOXO4-p53 interaction to induce apoptosis in senescent cells.
01 · At a glance
| Decision factor | FOXO4-DRI | Humanin |
|---|---|---|
| Primary fit | longevity & anti-aging research where you want a clear starting point | longevity & anti-aging and cognitive & neuroprotection comparisons |
| Evidence | Tier C | Tier C |
| Risk | high | med-high |
| Experience level | advanced | advanced |
| Budget tier | premium | premium |
| Administration route | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | FOXO4-DRI | Humanin |
|---|---|---|
| Goal fit | Longevity & Anti-Aging | Longevity & Anti-Aging, Cognitive & Neuroprotection |
| What users compare it for | Preclinical: selective elimination of senescent cells. No proven human benefit. | Preclinical: cytoprotection, neuroprotection. No proven human benefit. |
| Onset timeline | Mouse outcomes assessed over days to weeks, depending on tissue model. | Model-dependent in preclinical studies. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | FOXO4-DRI | Humanin |
|---|---|---|
| Adverse effects | Unknown in humans; high-risk category. | Unknown in humans. |
| Contraindications | No human data. | No data. |
| Interaction notes | Unknown; do not propose combinations. | Unknown. |
| Regulatory status | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA status unclear |
| WADA status | Not listed | Not listed |
04 · Age & monitoring
| Decision factor | FOXO4-DRI | Humanin |
|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet |
| Life-stage note | Not yet documented | Not yet documented |
| Monitoring burden | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | FOXO4-DRI | Humanin |
|---|---|---|
| Typical cycle cost | €96.35 | No reliable estimate yet |
| Estimated monthly cost | €96.35 | No reliable estimate yet |
| Cost confidence | High confidence | No estimate |
06 · Before you buy
| Decision factor | FOXO4-DRI | Humanin |
|---|---|---|
| Tracked vendor listings | 1 listing | 0 listings |
| Sourcing note | Tracked product pages are available, which makes it easier to review the listing before you click out. | No tracked product page yet, so sourcing takes more manual review. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.